DHAP (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 0
(D)examethasone 40 mg PO qd Days 1-4
(H)igh-dose Ara-C - cytarabine 2000 mg/m2 IV infusion over 2 hrs Day 2, every 12 hours
(P)latinol (cisplatin) 100 mg/m2 IV infusion over 24 hrs Day 1

References[edit]